These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 8734676)

  • 1. Stability of an extemporaneously compounded levothyroxine sodium oral liquid.
    Boulton DW; Fawcett JP; Woods DJ
    Am J Health Syst Pharm; 1996 May; 53(10):1157-61. PubMed ID: 8734676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions.
    Svirskis D; Lin SW; Brown H; Sangaroomthong A; Shin D; Wang Z; Xu H; Dean R; Vareed P; Jensen M; Wu Z
    Int J Pharm Compd; 2018; 22(2):164-171. PubMed ID: 29877863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of flucytosine in an extemporaneously compounded oral liquid.
    Wintermeyer SM; Nahata MC
    Am J Health Syst Pharm; 1996 Feb; 53(4):407-9. PubMed ID: 8673661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of nifedipine in an extemporaneously compounded oral solution.
    Dentinger PJ; Swenson CF; Anaizi NH
    Am J Health Syst Pharm; 2003 May; 60(10):1019-22. PubMed ID: 12789873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid.
    Levinson ML; Johnson CE
    Am J Hosp Pharm; 1992 Jan; 49(1):122-5. PubMed ID: 1570852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of acetazolamide in suspension compounded from tablets.
    Alexander KS; Haribhakti RP; Parker GA
    Am J Hosp Pharm; 1991 Jun; 48(6):1241-4. PubMed ID: 1858804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of an extemporaneously compounded baclofen oral liquid.
    Johnson CE; Hart SM
    Am J Hosp Pharm; 1993 Nov; 50(11):2353-5. PubMed ID: 8266961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of levofloxacin in an extemporaneously compounded oral liquid.
    VandenBussche HL; Johnson CE; Fontana EM; Meram JM
    Am J Health Syst Pharm; 1999 Nov; 56(22):2316-8. PubMed ID: 10582824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of lamotrigine in two extemporaneously prepared oral suspensions at 4 and 25 degrees C.
    Nahata MC; Morosco RS; Hipple TF
    Am J Health Syst Pharm; 1999 Feb; 56(3):240-2. PubMed ID: 10030509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of terbinafine hydrochloride in an extemporaneously prepared oral suspension at 25 and 4 degrees C.
    Abdel-Rahman SM; Nahata MC
    Am J Health Syst Pharm; 1999 Feb; 56(3):243-5. PubMed ID: 10030510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of warfarin sodium flavoured preservative-free oral liquid formulations.
    Schlatter J; Cisternino S
    Eur J Hosp Pharm; 2018 Oct; 25(e2):e98-e101. PubMed ID: 31157077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of ursodiol in an extemporaneously compounded oral liquid.
    Johnson CE; Nesbitt J
    Am J Health Syst Pharm; 1995 Aug; 52(16):1798-1800. PubMed ID: 8528836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of Extemporaneously Compounded Suspensions of Trimethoprim and Sulfamethoxazole in Amber Plastic Bottles and Amber Plastic Syringes.
    St-Jean I; Friciu MM; Monfort A; MacMahon J; Forest JM; Walker S; Leclair G
    Can J Hosp Pharm; 2021; 74(4):327-333. PubMed ID: 34602620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids.
    Allen LV; Erickson MA
    Am J Health Syst Pharm; 1996 Sep; 53(17):2073-8. PubMed ID: 8870895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of famotidine in an extemporaneously prepared oral liquid.
    Quercia RA; Jay GT; Fan C; Chow MS
    Am J Hosp Pharm; 1993 Apr; 50(4):691-3. PubMed ID: 8470686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids.
    Allen LV; Erickson MA
    Am J Health Syst Pharm; 1996 Sep; 53(18):2179-84. PubMed ID: 8879325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of ganciclovir in extemporaneously compounded oral liquids.
    Anaizi NH; Swenson CF; Dentinger PJ
    Am J Health Syst Pharm; 1999 Sep; 56(17):1738-41. PubMed ID: 10512505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment.
    Meissner S; Bansal M; Dela CPD; Hanning S; Svirskis D
    Int J Pharm Compd; 2020; 24(2):140-147. PubMed ID: 32196476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids.
    Allen LV; Erickson MA
    Am J Health Syst Pharm; 1996 Aug; 53(16):1944-9. PubMed ID: 8862208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids.
    Allen LV; Erickson MA
    Am J Health Syst Pharm; 1996 Oct; 53(19):2304-9. PubMed ID: 8893069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.